Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these proteasome inhibitors in combination with cyclophosphamide and dexamethasone (KCd vs. VCd) in second-line treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Kwee L., Hinsley, Samantha, Auner, Holger W., Bygrave, Ceri, Kaiser, Martin F., Ramasamy, Karthik, de Tute, Ruth M., Sherratt, Debbie, Flanagan, Louise, Garg, Mamta, Hawkins, Stephen, Williams, Catherine, Cavenagh, Jamie, Rabin, Neil K., Croft, James, Morgan, Gareth, Davies, Faith, Owen, Roger G., Brown, Sarah R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485692/
https://www.ncbi.nlm.nih.gov/pubmed/33910333
http://dx.doi.org/10.3324/haematol.2021.278399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485692/
https://www.ncbi.nlm.nih.gov/pubmed/33910333
http://dx.doi.org/10.3324/haematol.2021.278399

Ejemplares similares